biological product and a device, for instance, a biological tissue scaffold.

The responsibility for compliance regarding regulations may vary based on the lead component, which in turn defines which Center of the FDA will be primarily involved (CDER for drugs, CDRH for devices).

Gaining insight into the FDA’s comprehensive definition of combination products will better position you when advising on product development strategies and route to market.

Step 2: Selecting the Right Regulatory Pathway: 505(b)(2), NDA, BLA, or PMA

Choosing the appropriate regulatory pathway for your combination product can impact your development timeline and commercialization strategy. Here’s a breakdown of the most pertinent pathways:

• 505(b)(2) Application: This is a hybrid application that allows applicants to include data not developed by the applicant, facilitating a potentially faster approval process. Use this pathway if your product includes published literature or relies on investigations conducted by others.
• New Drug Application (NDA): Suitable for new drugs seeking marketing approval, this application demands extensive clinical data proving the safety and efficacy of the product.
• Biologics License Application (BLA): Focused on biological products, analogous to the NDA but tailored to biologics’ unique considerations.
• Premarket Approval (PMA): Exclusively for medical devices, a PMA represents the highest level of regulatory scrutiny, necessitating comprehensive clinical study evidence for safety and effectiveness.

It is recommended to conduct a thorough analysis of your product’s attributes, competitive landscape, and data availability when deciding on the regulatory pathway. Developing a detailed matrix to outline each pathway’s key requirements and suitability for your specific product type can serve as an excellent working document.

Step 3: Dossier Preparation and Compliance with Regulatory Standards

Once the regulatory strategy is determined, the next step entails meticulous dossier preparation. The documentation required varies based on the regulatory pathway selected.

For a 505(b)(2) submission: Applicants must prepare a Comprehensive Section, which can contain relevant sections taken from existing literature. Ensure you delineate which data was generated by the applicant versus what is cited from other sources.

For an NDA: Key elements include:

• Clinical and non-clinical laboratory study results
• Manufacturing information
• Labeling proposals
• Information on the safety and efficacy of the drug

For a BLA: Your dossier will consist of data demonstrating the safety, purity, and potency of the biological product, in light of its specific features.

For a PMA: Essential documentation involves:

• Clinical trial protocols and results
• Device specifications and components
• Manufacturing quality standards, akin to those described in ISO 13485 requirements

Familiarizing yourself with [FDA guidance on submission requirements](https://www.fda.gov/media/87537/download) is critical during dossier preparation to ensure compliance and expedite regulatory review.

Step 4: Submission Process and Communication with Regulatory Authorities

The submission process for each application can vary, necessitating careful navigation to avoid delays. For the 505(b)(2) and NDA pathways, consider the following milestones:

• Pre-Submission Meetings: Engage in early discussions with FDA review divisions to align on study design and data requirements.
• Submission Preparation: Utilize electronic Common Technical Document (eCTD) formats for submission as directed by the FDA to meet industry standards.

For PMA submissions:

• Prepare your application following the templates provided by the FDA to avoid common pitfalls.
• Conduct an internal review of the PMA before submission to ensure compliance with premarket requirements and format.

Communication is equally vital post-submission. Responding promptly to FDA queries can foster a collaborative review environment. Plan to establish structured updates—ideally during formal review periods—to confirm that all parties align on the status of the application.

Step 5: Review Process and Addressing Potential Deficiencies

Once submitted, be prepared for the FDA’s review process, which may involve multiple layers of scrutiny depending on the application pathway. Understanding the general framework of the review is crucial:

• Comprehensive Review: The FDA will assess the data presented. For 505(b)(2) applications, reviewers will heavily weigh literature support and prior designations.
• Deficiency Letters: If the FDA identifies data deficiencies, allow sufficient time to compile complete and robust responses. The quality of your responses can significantly affect approval timelines, so prepare to address each issue systematically.
• Advisory Committee Meetings: For PMAs and certain NDA/BLA products, your product may be evaluated by an advisory committee. Prepare an impactful presentation reflecting both regulatory and scientific perspectives on your product.

Step 6: Post-Approval Commitments and Marketing

Upon receiving approval, your obligations continue. Adhering to post-market commitments ensures ongoing compliance. Key considerations include:

• Risk Evaluation and Mitigation Strategies (REMS): Particularly for drugs or biologics where risk assessment is mandated. Providing adequate REMS to mitigate risks similar to those conveyed during the application phase is vital.
• Post-Market Surveillance Studies: Conduct required studies to satisfy post-marketing requests or conditions that address safety concerns highlighted during marketing.
• Periodic Safety Update Reports (PSUR): Establish a schedule for PSUR notifications as required by regulatory authorities.

Ensure your marketing strategies are consistent with submitted promotional materials to maintain compliance with the FDA’s promotional regulations. Any deviation could lead to significant penalties or enforcement actions.

Conclusion

Effectively navigating the regulatory landscape for combination products requires a well-defined strategy from initial concept through post-market commitments. By understanding the intricacies of pathways such as the 505(b)(2), NDA, BLA, and PMA, regulatory professionals can facilitate smoother transitions to market. Staying informed of the latest FDA guidance and actively engaging with regulatory authorities throughout the process are critical to success in FDA combination product consulting. You can access the FDA Combination Products homepage for further resources.